China Biologic Products Holdings Long Term Debt

China Biologic Products Holdings posts a long-term debt of $0 as of December 2020. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, China Biologic Products Holdings's long-term debt was $0. The latest reading is $0 (period ending December 2020). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of China Biologic Products Holdings's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CBPO's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; China Biologic Products Holdings's other metric pages and overview cover the third.

Judging China Biologic Products Holdings against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $0 here, then scan peer and history charts to see if the gap is persistent.